Effects of ivabradine on vascular endothelial function in patients with coronary artery disease：a meta-analysis
- VernacularTitle:伊伐布雷定对冠心病患者血管内皮功能影响的Meta分析
- Author:
Congling CHEN
1
,
2
;
Xian YANG
1
;
Han WU
3
;
Jiachen YING
1
,
2
;
Ruobin ZHANG
1
,
2
;
Xi LAN
3
;
Jinping ZHANG
1
Author Information
1. Dept. of Pharmacy，Nanjing Drum Tower Hospital，Nanjing 210008，China
2. School of Basic Medicine and Clinical Pharmacy，China Pharmaceutical University，Nanjing 211198，China
3. Dept. of Cardiology，Nanjing Drum Tower Hospital，Nanjing 210008，China
- Publication Type:Journal Article
- Keywords:
ivabradine;
vascular endothelial function
- From:
China Pharmacy
2024;35(6):744-749
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the effects of ivabradine on vascular endothelial function in patients with coronary artery disease. METHODS PubMed， Embase， the Cochrane Library， Web of Science， CNKI， Wanfang Data， VIP and CBM databases were retrieved to collect randomized controlled trials （RCTs） about ivabradine （intervention group） versus placebo or β-blocker （control group） from the inception to Mar. 20th 2023. The meta-analysis was performed by using RevMan 5.4 software after literature screening， data extraction and quality evaluation. RESULTS A total of 12 RCTs were included， involving 1 206 patients. The results of meta-analysis showed that the levels of flow-mediated dilation （FMD） [MD＝1.71， 95%CI （0.96， 2.46）， P＜0.000 01] and nitric oxide （NO） [MD＝5.80， 95%CI （5.02， 6.59）， P＜0.000 01] in the intervention group were significantly higher than control group， while endothelin-1（ET-1） level was significantly lower than control group [MD＝－7.45， 95%CI （－8.42， －6.47）， P＜0.000 01]. There was no statistical significance in nitroglycerin-mediated dilation （NMD） level between 2 groups [MD＝0.13， 95%CI（－0.74， 1.00）， P＝0.77]. Subgroup analyses based on the different medications and intervention time in the control group showed better improvement in FMD level of patients receiving ivabradine， compared with placebo （P＜0.05）； compared with placebo and β-blocker， the level of NO in patients receiving ivabradine was improved significantly （P＜0.05）， while ET-1 level was decreased significantly （P＜0.05）. Regardless of the duration of the intervention， the levels of FMD， NO， and ET-1 in the intervention group were significantly improved compared to the control group （P＜0.01）， while the difference in NMD was not statistically significant （P＞0.05）. CONCLUSIONS Ivabradine can improve vascular endothelial function in patients with coronary artery disease.
